Our work highlights the plasticity of DCs, provides insights in the development of DC3-like CD1c+CD14+ DCs with cDC2s as pre-cursor, and possibilities to modulate DCs for enhanced anti-tumor responses to improve cancer therapies outcomes. The gene discussed is CD1C; the disease is neoplasm.